Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ChromaDex Corporation - Common Stock (NQ: CDXC )

5.490 +0.080 (+1.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ChromaDex Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
4 Analysts Have This to Say About ChromaDex
ChromaDex (NASDAQ:CDXC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at the LD Micro Invitational
From ChromaDex Corporation
Via Business Wire
ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're closing in on the end of the week for trading as we go over the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Where ChromaDex Stands With Analysts
Within the last quarter, ChromaDex (NASDAQ:CDXC) has observed the following analyst ratings: 
Via Benzinga
Recap: ChromaDex Q4 Earnings
ChromaDex (NASDAQ:CDXC) reported its Q4 earnings results on Wednesday, March 9, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million. 
Via Benzinga
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
From ChromaDex Corporation
Via Business Wire
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
From ChromaDex Corporation
Via Business Wire
Recap: ChromaDex Q1 Earnings
ChromaDex (NASDAQ:CDXC) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex missed estimated earnings... 
Via Benzinga
ChromaDex Corporation Reports First Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
From ChromaDex Corporation
Via Business Wire
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
From ChromaDex Corporation
Via Business Wire
Recap: ChromaDex Q3 Earnings
ChromaDex (NASDAQ:CDXC) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:02 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
From ChromaDex Corporation
Via Business Wire
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
From ChromaDex Corporation
Via Business Wire
Earnings Scheduled For March 9, 2022
Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
From ChromaDex Corporation
Via Business Wire
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements
ChromaDex Corp (NASDAQ:CDXC) has 
Via Benzinga
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation (CDXC) Q3 2021 Earnings Call Transcript
CDXC earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
From ChromaDex Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
From ChromaDex Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.